US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Defiance Autism Impact ETF

27.62

-0.0977-0.35%

Volume:16

Turnover:467

Market Cap:1.38M

PE:- -

High:27.62

Open:27.72

Low:27.62

Close:27.72

52wk High:29.12

52wk Low:24.54

Shares:50.00K

Float Shares:50.00K

Volume Ratio:0.11

T/O Rate:0.03%

Dividend:0.01

Dividend Rate:0.02%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Qianli Intelligent Driving's ASD System Surpasses 530,000 Installations, Integrated into 19 Models Including Smart

Neurotech raises $4.5m to fund pivotal ASD Phase III trial

Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/ASD"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASD\",,,,,undefined,":{"symbol":"ASD","market":"US","secType":"STK","nameCN":"Defiance Autism Impact ETF","latestPrice":27.6173,"timestamp":1788206400000,"preClose":27.715,"halted":0,"volume":16,"delay":0,"changeRate":-0.00352516687714233,"floatShares":50000,"shares":50000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.0977,"latestTime":"09-01 09:18:10 EDT","open":27.715,"high":27.6173,"low":27.6173,"amount":467,"amplitude":0,"askPrice":41.42,"askSize":101,"bidPrice":13.81,"bidSize":101,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788269400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":27.6173,"nav":27.69,"aum":1384500,"dividendRate":0.000216,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.715,"preClose":27.6173,"latestTime":"16:10 EDT","volume":8,"amount":220.9384,"timestamp":1788207004002,"change":0.0977,"changeRate":0.003538,"amplitude":0},"volumeRatio":0.1126759214443194},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASD\",,,,,undefined,":{"symbol":"ASD","floatShares":50000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.1126759214443194,"shares":50000,"dividePrice":0.00597,"high":27.6173,"amplitude":0,"preClose":27.715,"low":27.6173,"week52Low":24.54,"pbRate":"--","week52High":29.12,"institutionHeld":0,"latestPrice":27.6173,"eps":0,"divideRate":0.000216,"volume":16,"delay":0,"ttmEps":0,"open":27.715,"prevYearClose":29.12,"prevWeekClose":27.715,"prevMonthClose":27.6173,"prevQuarterClose":26.76,"fiveDayClose":28.0793,"twentyDayClose":26.7397,"sixtyDayClose":25.1156},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASD\",params:#limit:5,,,undefined,":[{"date":"2026-06-24","symbol":"ASD","amount":0.00597,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-24","defaultRemindTime":1782307800000,"name":"Defiance Autism Impact ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-24","currency":"USD","dateTimestamp":1782273600000,"payDate":"2026-06-25"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASD\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-24","recordDate":"2026-06-24","paymentDate":"2026-06-25","value":0.00597,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASD\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659162663","title":"Press Release: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162663","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162663?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"trial of ML-007C-MA in adults with schizophrenia experiencing an acute. exacerbation of psychosis. The trial met its primary endpoint, with the. 210/3 mg twice-daily dose demonstrating a statistically significant and. clinically meaningful reduction in PANSS total score compared with. -- ML-007C-MA also demonstrated improvement on a prespecified. impairment and significant separation on key secondary endpoints,including CGI-S and the PANSS Marder positive factor.-- ML-007C-MA was generally well tolerated, with no serious or drug-related. severe adverse events and low rates of GI-related discontinuations. Its. clinical profile, including simple initiation, 99% of patients reaching","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UYG","IE000F7OJYX1.SGD","BK4559","LU0056508442.USD","LU1145028129.USD","LU0006306889.USD","LU2347655073.USD","LU1084165304.USD","IE000WAW04H5.SGD","IYG","LU2361044865.SGD","FDFF","FNCL","LU2462157665.USD","IPAY","LU2417539215.USD","LU2404859667.USD","IE00B1XK9C88.USD","VFH","XLF","IE0005OL40V9.USD","IE00BJJMRX11.SGD","LU2764262908.HKD","IE00BQXX3C00.GBP","LU0061474705.USD","LATR","LU1316542783.SGD","LU0965509010.AUD","LU2360107671.USD","LU0672654240.SGD","LU2168564222.USD","MA","LU0234570918.USD","LU0868494617.USD","LU1236620750.USD","BK4585","LU0942090050.USD","LU1623119135.USD","IE00B775H168.HKD","LU0174119429.USD","LU2023250504.SGD","MPLT","LU0353189763.USD","ADP","LU1989764748.USD","BK4613","LU1718418525.SGD","ASD","STBQ","IE00BYQQ9H92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136535851","title":"Qianli Intelligent Driving's ASD System Surpasses 530,000 Installations, Integrated into 19 Models Including Smart","url":"https://stock-news.laohu8.com/highlight/detail?id=1136535851","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136535851?lang=en_us&edition=fundamental","pubTime":"2026-08-08 16:20","pubTimestamp":1786177220,"startTime":"0","endTime":"0","summary":"Qianli Intelligent Driving has announced that its ASD 4.0 assisted driving system has been production-ready and launched in the new smart #1, following its earlier integration in the smart #6. This...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656886125","title":"Neurotech raises $4.5m to fund pivotal ASD Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656886125","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656886125?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:38","pubTimestamp":1785800292,"startTime":"0","endTime":"0","summary":"An announcement from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has secured binding commitments for a $4.5 mil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurotech-raises-4-5m-to-fund-pivotal-asd-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurotech-raises-4-5m-to-fund-pivotal-asd-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["III","BK4134","ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654704201","title":"Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654704201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654704201?lang=en_us&edition=fundamental","pubTime":"2026-07-28 02:23","pubTimestamp":1785176580,"startTime":"0","endTime":"0","summary":"-- Positive clinical data presented at EHA for iadademstat in first line. in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS. mutations; the triplet continued to demonstrate a favorable safety. gilteritinib continued to show a favorable safety profile and a high CRc. -- Enrollment initiated in Phase II trial of iadademstat in essential. -- U.S. patent granted for vafidemstat in borderline personality disorder. -- Cash position as of June 30, 2026 was $16.7 million ,excluding the gross proceeds of EUR12.0 million  raised in. -- On July 1, 2026, the company entered into a financing agreement with. COFIDES with a commitment to invest EUR25 million in future capital","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","NCI","ET","CR","BK4144","ASD","AMZA","BK4590","EIPI","EIPX","SCD","MLPA","BK4581","ENFR","EMLP","MDST","UMI","BK4202","BK4585","TNGY","TPZ","USAI","AMLP","BK4561","ORR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ASD\",params:#limit:6,delay:false,,,undefined,":[]}}